Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application.

BACKGROUND Continuous glucose monitors (CGMs) collect detailed blood glucose (BG) time series, which carry significant information about the dynamics of BG fluctuations. In contrast, the methods for analysis of CGM data remain those developed for infrequent BG self-monitoring. As a result, important information about the temporal structure of the data is lost during the translation of raw sensor readings into clinically interpretable statistics and images. METHODS The following mathematical methods are introduced into the field of CGM data interpretation: (1) analysis of BG rate of change; (2) risk analysis using previously reported Low/High BG Indices and Poincare (lag) plot of risk associated with temporal BG variability; and (3) spatial aggregation of the process of BG fluctuations and its Markov chain visualization. The clinical application of these methods is illustrated by analysis of data of a patient with Type 1 diabetes mellitus who underwent islet transplantation and with data from clinical trials. RESULTS Normative data [12,025 reference (YSI device, Yellow Springs Instruments, Yellow Springs, OH) BG determinations] in patients with Type 1 diabetes mellitus who underwent insulin and glucose challenges suggest that the 90%, 95%, and 99% confidence intervals of BG rate of change that could be maximally sustained over 15-30 min are [-2,2], [-3,3], and [-4,4] mg/dL/min, respectively. BG dynamics and risk parameters clearly differentiated the stages of transplantation and the effects of medication. Aspects of treatment were clearly visualized by graphs of BG rate of change and Low/High BG Indices, by a Poincare plot of risk for rapid BG fluctuations, and by a plot of the aggregated Markov process. CONCLUSIONS Advanced analysis and visualization of CGM data allow for evaluation of dynamical characteristics of diabetes and reveal clinical information that is inaccessible via standard statistics, which do not take into account the temporal structure of the data. The use of such methods improves the assessment of patients' glycemic control.

[1]  B P Kovatchev,et al.  Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. , 1998, Diabetes care.

[2]  I. Hirsch,et al.  Should minimal blood glucose variability become the gold standard of glycemic control? , 2005, Journal of diabetes and its complications.

[3]  Marimuthu Palaniswami,et al.  Do existing measures of Poincare plot geometry reflect nonlinear features of heart rate variability? , 2001, IEEE Transactions on Biomedical Engineering.

[4]  D. Klonoff.  Continuous glucose monitoring: roadmap for 21st century diabetes therapy. , 2005, Diabetes care.

[5]  Steven M. Pincus.  Approximating Markov chains. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P. Cryer.  Hypoglycemia: The Limiting Factor in the Management of IDDM , 1994, Diabetes.

[7]  David Kerr,et al.  Performance of a continuous glucose monitoring system during controlled hypoglycaemia in healthy volunteers. , 2002, Diabetes technology & therapeutics.

[8]  Daniel J Cox,et al.  Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. , 2003, Diabetes technology & therapeutics.

[9]  Yan Wang,et al.  Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. , 2003, Diabetes care.

[10]  C. McDonnell,et al.  A novel approach to continuous glucose analysis utilizing glycemic variation. , 2005, Diabetes technology & therapeutics.

[11]  Antonio Ceriello,et al.  Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. , 2003, Diabetes.

[12]  R. Marfella,et al.  Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus , 2004, Circulation.

[13]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[14]  Daniel J Cox,et al.  Methods for quantifying self-monitoring blood glucose profiles exemplified by an examination of blood glucose patterns in patients with type 1 and type 2 diabetes. , 2002, Diabetes technology & therapeutics.

[15]  Martin Straume,et al.  Risk Analysis of Blood Glucose Data: A Quantitative Approach to Optimizing the Control of Insulin Dependent Diabetes , 2000 .

[16]  J. Santiago.  Lessons From the Diabetes Control and Complications Trial , 1993, Diabetes.

[17]  D. Cox,et al.  Symmetrization of the Blood Glucose Measurement Scale and Its Applications , 1997, Diabetes Care.

[18]  C. Saudek,et al.  Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. , 2003, Diabetes.

[19]  Michael R. Rickels,et al.  β-Cell Function Following Human Islet Transplantation for Type 1 Diabetes , 2005 .

[20]  C. C. Palerm,et al.  Hypoglycemia prediction and detection using optimal estimation. , 2005, Diabetes technology & therapeutics.

[21]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[22]  F J Snoek,et al.  Symptoms and Well-Being in Relation to Glycemic Control in Type II Diabetes , 1996, Diabetes Care.

[23]  D. Cox,et al.  Evaluating the accuracy of continuous glucose-monitoring sensors: continuous glucose-error grid analysis illustrated by TheraSense Freestyle Navigator data. , 2004, Diabetes care.

[24]  Ronald Brazg,et al.  A continuous glucose sensor based on wired enzyme technology -- results from a 3-day trial in patients with type 1 diabetes. , 2003, Diabetes technology & therapeutics.

[25]  P. Cryer,et al.  Hypoglycemia in diabetes. , 2003, Diabetes care.

[26]  Steven M. Pincus,et al.  A regularity statistic for medical data analysis , 1991, Journal of Clinical Monitoring.

[27]  M. Hanefeld,et al.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up , 1996, Diabetologia.

[28]  Walter Devillé,et al.  Well-Being and Symptoms in Relation to Insulin Therapy in Type 2 Diabetes , 1998, Diabetes Care.

[29]  P. Cryer,et al.  Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes* , 2002, Diabetologia.